陳百昇  Pai-Sheng Chen, Ph.D.

  辦公室地點：醫技系四樓5795B室

  辦公室電話：6233

  實驗室電話：6234

  實驗室地點：醫技系四樓5795B室

  電子信箱：bio.benson@gmail.com

  學術成大：陳 百昇

  Publons：Pai-Sheng Chen 

MyLab實驗室研究方向

Our research goal is using RNA as a diagnostic and therapeutic target/tool in cancer. Tumor metastasis is a key step in facilitating cancer progression, which is theoretically an irreversible and lethal process. We mainly focus on investigating the mechanism of how cancer cells acquire the capacity to metastasize along with the possible therapeutic and diagnostic strategies. Cellular functions rely on fine-tuned regulation from DNA to RNA to protein (central dogma). As a carrier for genetic information, RNA has long been widely-recognized as a messenger for protein coding. For recent decades, a large number of accumulating research has identified new functions of noncoding RNAs (miRNA, lincRNA, circRNA, etc.), such as gene silencing, epigenetic, and protein modification. We devote ourselves to understanding the regulation of RNA processing and the resulting impact in cancer. Since most noncoding RNAs act as RNA-protein complexes (RNPs), we focus on studying the pathophysiological roles of RNA and RNA-binding protein in human cancer.

Research Field

RNA-binding protein

Post-translational regulation

Precision oncology

指導學生

無相關資料

指導學生之特殊榮譽

無相關資料

榮譽及獎勵

1.    科技部優秀年輕學者研究計畫獎助: Functional mechanism of Hypoxia-inducible factor-1alpha-meidated Dicer downregulation and miRNA biogenesis (MOST 103-2628-B-006-003-MY3) (2014-2017)

2.    指導賴輝寰博士生榮獲第28屆王民寧獎之「國內醫藥研究所博士班優秀論文獎」(2018)

3.    指導賴輝寰博士生榮獲柯林論文獎生物醫學領域博士論文獎(2019)

4.    成功大學110學年度教學特優教師(2022)

5.    成功大學110學年度輔導優良教師(2022)

6.    科技部2030跨世代年輕學者方案-優秀年輕學者研究計畫獎助(2022-2025)

7.    科技部111年度吳大猷先生紀念獎(2022)

8.   指導曾培雅碩士生榮獲生物醫學聯合學術年會細胞及分子生物學學會永信李天德醫藥基金會壁報論文獎(2023)

9.   國科會112年度吳大猷先生紀念獎獎助計畫(2023-2026)

Selected Publications Within Five Years

近五年以第一/通訊作者發表期刊論文(2017/01/01至今)

1.    Hui-Huang Lai, Jie-Ning Li, Ming-Yang Wang, Hsin-Yi Huang, Carlo M. Croce, Hui-Lung Sun, Yu-Jhen Lyu, Jui-Wen Kang, Ching-Feng Chiu, Mien-Chie Hung, Hiroshi I. Suzuki, Pai-Sheng Chen* (2018, Feb). HIF-1α promotes autophagic proteolysis of Dicer and enhances tumor metastasis. Journal of Clinical Investigation, 2018 Feb 1;128(2):625-643. doi: 10.1172/JCI89212. (R/C=2/139; 1.44%, MEDICINE, RESEARCH & EXPERIMENTAL, IF=19.486) *本人為通訊作者 / 指導第一作者賴輝寰博士生獲第28屆王民寧獎之「國內醫藥研究所博士班優秀論文獎」以及柯林論文獎生物醫學領域博士論文獎

2.    Hui-Huang Lai, Pai-Sheng Chen* (2018, Aug). Dual mechanism of Dicer downregulation facilitates cancer metastasis. Molecular & Cellular Oncology, 24;5(5):e1472056. doi: 10.1080/23723556.2018.1472056. eCollection 2018. *本人為通訊作者.

3.    Hui-Huang Lai, Li-Jyuan Lin, Liang-Yi Hung and Pai-Sheng Chen* (2018, Nov). Role of Dicer in regulating oxaliplatin resistance of colon cancer cells. Biochemical and Biophysical Research Communications, 506:87-93. pii: S0006-291X(18)32227-7. doi: 10.1016/j.bbrc.2018.10.071. [Epub ahead of print]. MOST 107-2320-B-006-009. (R/C=196/296; 66.22%, BIOCHEMISTRY & MOLECULAR BIOLOGY, IF=3.322) *本人為通訊作者.

4.    Hui-Huang Lai, Chih-Wei Li, Chih-Chen Hong, Hung-Yu Sun, Da-Liang Ou, Pai-Sheng Chen* (2019 , Jan). TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Molecular Oncology, 2019 Jan 18. doi: 10.1002/1878-0261.12449. [Epub ahead of print]. MOST 107-2320-B-006-068. (R/C=51/245; 20.82%, ONCOLOGY, IF=7.449) *本人為通訊作者.

5.    Ming-Yang Wang, Hsin-Yi Huang, Yao-Lung Kuo, Chiao Lo, Hung-Yu Sun, Yu-Jhen Lyu, Bo-Rong Chen, Jie-Ning Li, Pai-Sheng Chen*. (2019, Feb). TARBP2-Enhanced Resistance During Tamoxifen Treatment in Breast Cancer. Cancers, 2019, 11(2), 210; doi.org/10.3390/cancers11020210. European Patent Approved No. 3 539 541 (成功大學優質專利) (R/C=60/245; 24.49%, ONCOLOGY, IF=6.575) *本人為通訊作者.

6.    Pai-Sheng Chen^#, Shao-Chieh Lin, Shaw-Jenq Tsai* (2020, Mar). Complexity in Regulating microRNA Biogenesis in Cancer. Experimental Biology and Medicine, 245(5):395-401. doi: 10.1177/1535370220907314. Epub 2020 Feb 19. (R/C=76/139; 54.68%, MEDICINE, RESEARCH & EXPERIMENTAL, IF=2.691) ^#本人為第一作者.

7.    Pai-Sheng Chen^#, Wen-Tai Chiu, Pei-Ling Hsu, Shih-Chieh Lin, I-Chen Peng, Chia-Yih Wang, Shaw-Jenq Tsai* (2020, May). Pathophysiological Implications of Hypoxia in Human Diseases. Journal of Biomedical Science, 27(1):63. doi: 10.1186/s12929-020-00658-7. (R/C=11/139; 7.91%, MEDIICIINE, RESEARCH & EXPERIIMENTTAL, IF=12.771) ^#本人為第一作者.

8.    Jie-Ning Li, Hui-Lung Sun, Ming-Yang Wang, Pai-Sheng Chen* (2021, Jul). E-cadherin Interacts With Posttranslationally-Modified AGO2 to Enhance miRISC Activity. Frontiers in Cell and Developmental Biology, 9:671244. doi: 10.3389/fcell.2021.671244. eCollection 2021. (R/C=6/39; 15.38%, DEVELOPMENTAL BIOLOGY, IF=6.081) *本人為通訊作者.

9.    Jie-Ning Li, Ming-Yang Wang, Yi-Ting Chen, Yao-Lung Kuo, Pai-Sheng Chen* (2021, Dec). Expression of SnoRNA U50A Is Associated with Better Prognosis and Prolonged Mitosis in Breast Cancer. Cancers. 13(24):6304. doi: 10.3390/cancers13246304. European Patent Approved (成功大學優質專利) (R/C=60/245; 24.49%, ONCOLOGY, IF=6.575) *本人為通訊作者.

10.Yu-Yun Shao^#, Pai-Sheng Chen^#, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu & Da-Liang Ou* (2022, Mar). Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer. doi: 10.1038/s41416-022-01759-w. Online ahead of print. (R/C=37/245; 15.10%, ONCOLOGY, IF=9.089) ^#本人為共同第一作者.

11.Pai-Sheng Chen^#,* (2019, Feb). Regulation of Selective Proteolysis in Cancer. The Ubiquitin/Proteasome System. In production. Matthew Summers, editor, IntechOpen, London, UNITED KINGDOM. ISBN 978-953-51-7766-1 (Invited book chapter) ^#,*本人為第一作者兼通訊作者. 

Invited Talk

1.     A noncanonical HIF-1α pathway for metastasis control.第13屆海峽兩岸細胞生物學學術研討會 2018/07/18-22 (Invited speaker)

2.     Exoswitch: a rethink of HIF-1α. 成功大學醫學院教師研究討論會 2022/05/27 (Invited speaker)

Patents

   1.　Method of Evaluating Drug Resistance and Treatment Effect. European Patent #EP3539541 B1. Chen Pai-Sheng*, Li Jie-Ning, Kuo Yao-Lung, Wang Ming-Yang. 2020/12 Approved

   2.　Method of Evaluating Drug Resistance and Treatment Effect. US Patent #US 11,435,353 B2. Chen Pai-Sheng*, Li Jie-Ning, Kuo Yao-Lung, Wang Ming-Yang. 2022/09 Approved

   3.　Method and kit for the evaluation of the prognosis of breast cancer. European Patent #EP3540078. Chen Pai-Sheng*, Li Jie-Ning, Kuo Yao-Lung. 2022/10 Approved

Experience/Service

1. 國科會計畫複審委員

2. 國科會計畫初審委員

3. 國科會大專生研究計畫審查委員、

4. 國科會大專學生研究計畫創作獎審查委員

5. 國立臺灣大學高等教育深耕計畫─學術研究生涯發展研究計畫審查委員

6. 永信李天德醫藥科技獎審查委員

7. 成大醫院乳房醫學中心研究顧問

8. 經濟部工業局產業競爭力中心業界訪視服務專家

Invited SCI Journal Reviewer (Selected Journal list)

1.      Cancer Research (5)

2.      Cancer Communications (1)

3.      Oncogene (4)

4.      Drug Resistance Updates (2)

5.      Cancer Letters (2)

6.      Theranostics (6)

7.      Molecular Oncology (4)

8.      Therapeutic Advances in Medical Oncology (5)

9.      Oncogenesis (2)

10.    European Journal of Pharmacology (1)  

Editorial Board Member

　1.      BMC Cancer

　2.      Frontiers in Oncology

　3.      Frontiers in Cell and Developmental Biology